Regenxbio Inc (RGNX)
16.06
+0.02
(+0.12%)
USD |
NASDAQ |
Apr 25, 16:00
16.08
+0.02
(+0.12%)
Pre-Market: 20:00
Regenxbio Research and Development Expense (Quarterly): 55.68M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 55.68M |
| September 30, 2023 | 58.18M |
| June 30, 2023 | 59.89M |
| March 31, 2023 | 58.52M |
| December 31, 2022 | 62.50M |
| September 30, 2022 | 63.31M |
| June 30, 2022 | 61.01M |
| March 31, 2022 | 55.63M |
| December 31, 2021 | 47.98M |
| September 30, 2021 | 47.86M |
| June 30, 2021 | 45.88M |
| March 31, 2021 | 39.72M |
| December 31, 2020 | 47.18M |
| September 30, 2020 | 43.97M |
| June 30, 2020 | 38.11M |
| March 31, 2020 | 37.04M |
| December 31, 2019 | 33.81M |
| September 30, 2019 | 35.69M |
| June 30, 2019 | 29.48M |
| Date | Value |
|---|---|
| March 31, 2019 | 25.20M |
| December 31, 2018 | 24.33M |
| September 30, 2018 | 18.51M |
| June 30, 2018 | 21.49M |
| March 31, 2018 | 19.55M |
| December 31, 2017 | 14.17M |
| September 30, 2017 | 12.52M |
| June 30, 2017 | 13.92M |
| March 31, 2017 | 16.62M |
| December 31, 2016 | 16.06M |
| September 30, 2016 | 12.56M |
| June 30, 2016 | 10.68M |
| March 31, 2016 | 6.183M |
| December 31, 2015 | 4.808M |
| September 30, 2015 | 5.664M |
| June 30, 2015 | 4.012M |
| March 31, 2015 | 2.791M |
| December 31, 2014 | 2.092M |
| September 30, 2014 | 1.085M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
29.48M
Minimum
Jun 2019
63.31M
Maximum
Sep 2022
48.50M
Average
47.86M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 195.52M |
| Amgen Inc | 1.534B |
| Gilead Sciences Inc | 1.408B |
| AbbVie Inc | 1.927B |
| Bristol-Myers Squibb Co | 2.478B |